AstraZeneca-backed CDMO Nucleus RadioPharma to boost commercial capacity

As the ra­dio­phar­ma space heats up, CD­MO Nu­cle­us Ra­dio­Phar­ma is ex­pand­ing its com­mer­cial man­u­fac­tur­ing with two new fa­cil­i­ties to cater to po­ten­tial clients out­side North …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.